Lipella Pharmaceuticals
A biotechnology company that develops products for intravesical therapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $876k | Private Placement non VC |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (73 %) | (29 %) | 144 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6 %) | (717 %) | (1405 %) | (1025 %) | (935 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (6 %) | (719 %) | (1411 %) | (1027 %) | (935 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 101 % | 562 % | 1383 % | - | - |
Source: Company filings or news article
Related Content
Lipella Pharmaceuticals Inc. is a privately held biotechnology company specializing in supportive care for cancer survivors and advanced drug delivery systems. The company primarily serves patients who have developed hemorrhagic cystitis, a condition often seen in cancer survivors, and those with a history of transitional cell carcinoma. Lipella is also innovating in the treatment of oral lichen planus through its proprietary drug delivery technology.
Operating in the biotechnology and pharmaceutical markets, Lipella's business model revolves around the development and clinical trials of specialized treatments. The company is currently conducting a phase 2a, dose escalation clinical trial for LP 10 liposomal tacrolimus, aimed at treating hemorrhagic cystitis. This product has received US FDA Orphan Designation, which provides certain benefits and incentives for the development of treatments for rare diseases.
Lipella generates revenue through the development and potential commercialization of its proprietary treatments. The company also engages in partnerships and collaborations to advance its clinical trials and bring its products to market.
Keywords: biotechnology, cancer survivorship, hemorrhagic cystitis, drug delivery, oral lichen planus, clinical trials, FDA Orphan Designation, transitional cell carcinoma, supportive care, liposomal tacrolimus.